Entegrion, the RTP company that is working on a replacement for fresh frozen blood, has received $1.9 million from the U.S. Office of Naval Research.
The money will be used to further two technologies Entegrion is developing: a fluid that provides a safer and more readily available alternative to blood transfusion and dehydrated plasma, which can be used more easily in combat.
The Food and Drug Administration recently approved Entegrion's plans to begin Phase 1 studies on Resusix, the plasma substitute. The company's vice president Michael Galiger called the transition from preclinical to clinical development an important milestone.
“This advance combined with our military’s demonstrated confidence in our unique abilities to meet their complex requirements clearly establishes our position in the blood therapeutics market," Galiger said in a statement.
Entegrion is already working under a U.S. Department of Defense contract that provides $24 million for two years with the option for another $19.7 million over another two years.